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a  b  s  t  r  a  c  t
Neurocysticercosis  (NCC)  is  the  most  common  parasitic  disease  of  the human  central  nervous  system
(CNS),  a pleomorphic  disease  with  a diverse  array of  clinical  manifestations.  The  infection  is pleomorphic
and  dependent  on a complex  range  of  interconnecting  factors,  including  number  and  size  of  the  cys-
ticerci, their  stage  of  development  and  localisation  within  the  brain  with  resulting  difﬁculties  in  accurate
diagnosis  and  staging  of the  disease.  This  review  examines  the  factors  that contribute  to  the  accurate
assessment  of  NCC  distribution  and  transmission  that  are  critical  to achieving  robust disease  burden
calculations.
Control  and  prevention  of T.  solium  transmission  should  be a key  priority  in  global  health  as  interven-
tion  can  reduce  the  substantial  healthcare  and  economic  burdens  inﬂicted  by both  NCC  and  taeniasis.oonoses
eglected tropical diseases
aeniasis
estode
aenia solium
Surveillance  systems  need  to  be  better  established,  including  implementing  obligatory  notiﬁcation  of
cases.  In the absence  of  reliable  estimates  of  its global  burden,  NCC  will  remain-along  with  other  endemic
zoonoses,  of low  priority  in the  eyes  of funding  agencies–a  truly  neglected  disease.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-NDateral ﬂow assay
pilepsy
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Neurocysticercosis (NCC) is the most common parasitic disease
f the human central nervous system (CNS) (Del Brutto, 2012).
aused by the larval form of the cestode, Taenia solium,  commonly
eferred to as the ‘pork tapeworm’ (Fogang et al., 2015), NCC is
ot to be confused with ‘taeniasis’, the condition resulting from
dult tapeworm infection. Human or porcine NCC originates from
he ingestion of food or water that is contaminated with T. solium
ggs; these hatch within and then penetrate the intestine, following
hich, a period of widespread tissue dissemination occurs. Mul-
iple body tissues may  be invaded, including the eyes, skin and
uscles (WHO, 2016), however the larvae display a strong afﬁn-
ty for the CNS (Sinha and Sharma, 2009). NCC has a diverse array
f clinical manifestations, depending on a complex range of inter-
onnecting factors, including the number and size of the cysticerci
resent, their stage of development and localisation within the
rain with resulting difﬁculties in accurate diagnosis and staging
f the disease (Takayanagui and Odashima, 2006).
Aristotle was aware of NCC in 424 BCE, describing the presence
f muscle cysts, compared to hailstones in appearance, evident in
ertain porcine diseases (Del Brutto et al., 1998). Until the develop-
ent of CT and MRI  scans in the 20th century, knowledge of NCC
as very limited, as the majority of diagnoses were based on clinical
anifestations visible externally to the naked eye, such as presence
f subcutaneous nodules, or on post-mortem observations made
t autopsy (Garcia et al., 2002). This advance in diagnostic capa-
ilities was a watershed in our understanding of NCC, redeﬁning
rognoses. Previously only the severest cases had been apparent to
linicians, giving a distorted view of disease severity; advances in
canning allowed for the diagnosis of previously undetected milder
ases and further consideration was given to the spectrum of pre-
entations that existed (Garcia et al., 2002).
.1. Parasite lifecycle
T. solium belongs to the class Cestoda, one of the largest and
ost successful groups of parasitic tapeworms, comprising approx-
mately 5000 species. The family Taeniidae is divided into three
enera: Taenia (sub-divided into Taenia and Versteria; Nakao et al.,
013) of which T. solium is a species, and Echinococcus (Bobes et al.,
014).
The lifecycle of T. solium is complex and may  result in a range of
athologies, affecting both pigs and humans. Humans are the only
eﬁnitive hosts, within which the tapeworm can complete its life-
ycle and exist in adult form, however both humans and pigs have
een documented as intermediate hosts, in which the tapeworm
ggs can develop up to the metacestode larval stage (Coral-Almeida
t al., 2015). Dogs have also been implicated as intermediate hosts
n Asia (Ito et al., 2002).
.2. Typical lifecycle of T. solium
Human NCC, porcine NCC and dog NCC are mainly due to direct
ontact with human faeces. Humans become infected most com-
only through the ingestion of food or water contaminated with
. solium eggs; pigs and dogs through scavenging human faeces.
ggs come from an adult tapeworm that has reached maturity
n the small intestine of a human host entering the environment
ithin human faeces; one adult tapeworm can expel a minimum
f 100,000 eggs per day. Serological studies in endemic areas have
hown that eggs can be distributed in the environment at large dis-
ances from the infected individual (Lescano et al., 2009). It has also
een suggested that humans may  be able to autoinfect themselves
Kobayashi et al., 2013)ropica 166 (2017) 218–224 219
In the host intestinal tract, eggs become uncoated liberating
the enclosed larvae, known as oncospheres. These penetrate the
intestinal wall and are transported in the bloodstream to various
tissues of the body, including the brain, eyes, skin and muscles,
where they are deposited (Del Brutto, 2012). Within these tissues
oncospheres differentiate and develop into metacestodes, which
undergo multiple stages of development and establish as cys-
ticerci. The ﬁrst stage is known as the ‘viable or vesicular stage’
in which a membrane develops around each oncosphere, forming
a vesicle that contains clear ﬂuid surrounding the parasite head,
or scolex. Depending on the surrounding environment, and the
nature of the immune response their presence elicits, the cysts may
remain at this stage for months or even years, before they begin to
degenerate. The ‘colloidal stage’ marks this transition, whereby the
scolex shows signs of deterioration and the vesicular ﬂuid begins to
appear turbid. Following this, the vesicular ﬂuid becomes gradually
more opaque and the cyst begins to calcify, eventually terminating
its evolution as non-viable calciﬁed nodule (Coral-Almeida et al.,
2015).
The lifecycle is completed when humans ingest undercooked
pork containing viable cysticerci. Digestive enzymes in the small
intestine cause the scolices to evaginate from the cyst vesicle
and attach to the wall of the intestine using powerful suckers
and hooks. Here, the tapeworm matures to adulthood, at which
point egg-containing sections of the tapeworm body, called ‘gravid
proglottids’, are released in the host’s faeces (Del Brutto, 2012).
This part of the tapeworm lifecycle accounts for the disease taeni-
asis only; it is a common misconception that eating undercooked
pork can result in cysticercosis.
2. Epidemiology
Despite being one of the most prevalent parasitic disease of the
human CNS (Fabiani and Bruschi, 2013), NCC remains a neglected
tropical disease, recognised in 2010 by the World Health Organi-
sation (WHO, 2016). Despite its substantial global impact, in terms
of both disease and economic burden, there are limited data for
accurate assessment of distribution and transmission (Crompton
and Peters, 2010). However, awareness of cysticercosis is increas-
ing (Ito and Budke, 2014) and bodies such as WHO  have put forward
improved strategies for the control of both taeniasis and cysticer-
cosis (WHO, 2016).
2.1. Endemicity of NCC
NCC particularly affects countries burdened by poverty, as lack
of adequate sanitation and inaccessibility of clean water supplies
increase contamination of both food and water with human fae-
ces containing T. solium eggs. Countries where NCC is endemic may
also have high numbers of free-roaming pigs that are exposed to
human faeces, leading to increased incidence of porcine NCC (Coyle
et al., 2012). Once established within a population, the taeniasis-
cysticercosis complex shows high epidemiological stability, due
to a number of factors, including the durability of the eggs and
the potential for a single tapeworm to infect multiple individu-
als including the tapeworm carrier (Kobayashi et al., 2013); this
has contributed substantially to logistical difﬁculties in infection
control (Fabiani and Bruschi, 2013).
Areas endemic for NCC include Latin America, Africa, South East
Asia, India, China and Nepal (Fabiani and Bruschi, 2013). Differences
are observed the clinical and radiological presentations of NCC
between countries in different continents. Patients in India show
higher frequency of symptomatic NCC caused by a single, isolated,
parenchymal cysticercus, compared to patients in Latin America,
who more frequently exhibit multiple cysticerci in the ventricles
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r subarachnoid space (Bobes et al., 2014). This may  reﬂect genetic
ispositions associated with varying presentations between geo-
raphical areas and differing lifestyles among human populations
Yanagida et al., 2014), where the infection was acquired (Yanagida
t al., 2010), as well as genetic differences between parasite popu-
ations (Ito et al., 2016).
Despite a lack of accurate prevalence data, various studies have
pplied statistical methods to approximate disease burden (Coyle
t al., 2012). These burden estimates indicate the relative impact
f the disease in certain areas of the world, but would be much
mproved if based on population-based data generated from large-
cale studies and improved in-country, surveillance and reporting
ystems-few of which currently exist (Martins-Melo et al., 2016).
ultiple obstacles lead to high variability between individual stud-
es, preventing the acquisition of accurate epidemiological data for
CC; these include inadequacy of current assays leading to missed
iagnoses and subsequent underestimations, as well as discrepan-
ies between studies as to whether or not to include cases involving
alciﬁed cysts in prevalence calculations as well as resourcing.
.2. Increasing incidence in Low and Middle Income Countries
LMIC)
There have been observations of increasing incidence of NCC
n high income countries, particularly in the USA, where over
000 infected patients have been reported in recent years (Sorvillo
t al., 2011), as well as in Canada and Europe (Coyle et al., 2012)
ttributed to increasing rates of immigration. The great biotic
otential of tapeworms represents a signiﬁcant risk of sustained
ropagation within these newly-established populations; this risk
s compounded by the relative inexperience in handling such par-
sitic infections.
. Clinical presentation
The pleomorphic nature of clinical presentations associated
ith NCC can be attributed to many factors. The parasite load,
ependent on both the size and number of cysticerci, is an impor-
ant determinant of symptomatology; high loads are associated
ith increased risk of obstruction and corresponding rises in
ntra-cranial pressure (ICP) as well as induction of signiﬁcant
nﬂammatory responses (Singhi and Suthar, 2015). In very severe
ases, involving numerous cysts with associated inﬂammation, an
ncephalitic state can occur with diffuse cerebral oedema; such
ases have a very poor prognosis (Kimura-Hayama et al., 2010).
The stage of cysticercus development is a crucial factor in the
ontrol of immune interactions. It is thought that viable cysts ini-
iate a complex immune evasion response, allowing them to exist
ndetected in the body; this may  persist for a prolonged period of
ime, with immune-mediated symptoms sometimes being delayed
or several, or as many as 10 years (Kimura-Hayama et al., 2010;
anagida et al., 2010).
Development of symptoms is generally associated with the
mmune system overcoming such evasion mechanisms and ini-
iating subsequent immune responses against the degenerating
yst, leading to systemic effects and a corresponding clinical pro-
le (Garcia et al., 2010). This process may  be accelerated by
nti-helminthic drug treatment, and clinicians are cautious when
rescribing such medication to patients with high parasite loads
Tuero et al., 2015).Finally, cyst location is a key determinant of clinical presenta-
ion, with clusters of symptoms showing patterns of association
ith affected areas of the CNS. In general, cyst location is broadly
lassiﬁed as either parenchymal, within the functional tissues of theropica 166 (2017) 218–224
brain, or extra-parenchymal, which encompasses the remaining
locations within the CNS (Garcia et al., 2002).
3.1. Parenchymal NCC
The brain parenchyma is most commonly infected with NCC
(Bansal et al., 2014) with high rates of cyst deposition occurring at
junctions separating grey matter from white matter; this is thought
to be due to accumulation of metacestodes in the small terminal
blood vessels that converge here. Parenchymal disease generally
has a more favourable prognosis than extra-parenchymal, with
seizures and headaches, tending to resolve independently with
time, being the most consistently reported manifestations (Singhi
and Suthar, 2015). Psychiatric symptoms have been reported on
occasion, however the majority of studies have found this to be
a rare occurrence, presenting in approximately 5% of NCC cases
(Carabin et al., 2011). Importantly, it should be noted that the
burden of NCC-associated disease is commonly overestimated, as
asymptomatic or only mildly symptomatic patients very rarely
present at neurology clinics; as many as 50% of NCC cases had no
history of symptoms (Carabin et al., 2011).
The link between NCC and epilepsy is implied to be a causal
relationship by the majority of studies, but to assume causality-
not simply high rates of co-occurrence-is unwise without further
analysis of the discrepancies that are evident in existing studies.
Deﬁnitions as to what distinguishes epilepsy from seizures need to
be more clearly established; by deﬁnition ‘epilepsy’ is the occur-
rence of recurrent and unprovoked seizures, therefore seizures
related to active cysticerci would be classiﬁed as ‘acute symp-
tomatic seizures’, which are not synonymous with epilepsy (Carpio
and Romo, 2014). Terminology aside, there still exist further issues
with some of the conclusions drawn from certain aspects of the
literature on this topic. Several reports use seropositivity inferred
from enzyme-linked immuno-electrotransfer blot (EITB) assay as
a deﬁnitive indicator of active NCC infection, despite both the
accepted inaccuracies of this method and the fact that presence
of T. solium antibodies does not conclusively specify active disease,
nor CNS involvement; such work may  therefore misrepresent the
epidemiology of the epilepsy-NCC relationship (Carpio and Romo,
2014). There also exists an evident selection bias in certain stud-
ies, where sample populations have high rates of both epilepsy and
NCC; an incidental relationship must ﬁrst be considered, as well
as the potential for genetic predisposition in certain geographical
areas showing high rates of familial aggregation of NCC (Carpio
and Romo, 2014). Whilst the high co-prevalence of the two  condi-
tions certainly provides a strong indication of a causal relationship,
these factors highlight ﬂaws in a hypothesis that seems to have
been widely accepted.
3.2. Extra-Parenchymal NCC
Clinical manifestations of extra-parenchymal NCC show greater
heterogeneity than those associated with parenchymal disease, as
a wide range of locations throughout the CNS are included within
this broad deﬁnition. In general, extra-parenchymal disease has a
poorer prognosis than parenchymal, as parasite loads tend to be
higher, and growth of individual cysticerci is less restricted and
tends to be more irregular; this is associated with higher rates of
morbidity and mortality (Tuero et al., 2015).
The most common location of extra-parenchymal NCC is in the
subarachnoid spaces and associated meninges (Kimura-Hayama
et al., 2010). In severe cases, subarachnoid NCC can trigger mass
inﬂammation in this area, leading to arachnoiditis; this can have
multiple effects of signiﬁcant severity, one example being the
development of a hydrocephalic state, in which severe oedema
leads to a sharp increase in ICP (Callacondo et al., 2012). Thickening
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f the inﬂamed meninges, along with oedema, may  also impact sur-
ounding nerves leading to entrapment of components of the CNS
uch as the optic chiasm and cranial nerves with an assortment
f nerve palsies and visual impairments (Kimura-Hayama et al.,
010). Another mechanism by which hydrocephalus can occur is
hrough the obstruction of cerebro-spinal ﬂuid (CSF) ﬂow, either
ue to high parasite burden in the subarachnoid space, or through
yst deposition in the ventricular system. Prognosis for subarach-
oid disease is further impacted by the occasional development of
 proliferating cyst cluster, which forms through the aggregation of
bnormal vesicles, known as a ‘racemose cyst’ (Bansal et al., 2014).
nrestricted growth of a racemose cyst can lead to invasion of var-
ous brain spaces, and increases the likelihood of obstruction of
SF pathways or severe inﬂammatory reactions (Callacondo et al.,
012).
The vascular networks of the brain are similarly affected by
bstruction from cysticerci and inﬂammatory exudates; there may
lso be direct insult to the blood vessels themselves in the form of
asculitis. Consequential disruption to blood ﬂow can lead to tran-
ient or prolonged vascular incidents such as stroke (Callacondo
t al., 2012).
Circulating CSF within the subarachnoid space communi-
ates directly with CSF surrounding the spinal column and, as
 result, cysts originating in the basal cisterns may  follow a
ravity-dependent downwards course and disseminate within the
pinal meninges. Spinal NCC is rare (Jongwutiwes et al., 2011),
ith a reported frequency of approximately 0.25%–5.8% of cases
Callacondo et al., 2012) and infrequently presents in isolation
ithout concomitant cranial involvement (Kimura-Hayama et al.,
010). This may  present as motor and sensory dysfunction, related
o the level at which the lesion occurs (Del Brutto, 2012). Symptoms
ay  include paraesthesia and radicular pain, along the nerve roots
nto the lower extremities (Singhi and Suthar, 2015).
. Diagnosis
Accurate diagnosis of NCC is notoriously difﬁcult; available
ethods are problematic and implementation in resource-poor
ndemic is patchy. Del Brutto et al. (2001) proposed a set of diag-
ostic criteria in an attempt to combine aspects of clinical history,
euroimaging and immunological evidence, as well as epidemio-
ogical factors, to form deﬁned guidelines for the diagnosis of NCC
see Table 1). This multifaceted approach allows for a diagnosis to
e made in the absence of criteria that may  be untestable in certain
ituations.
Using available evidence, a positive diagnosis can be deemed
s either ‘deﬁnitive’ or ‘probable’ based on the weight attributed to
he criteria that have been met. While not systematically validated,
his approach does allow for otherwise unattainable diagnoses to
e made in difﬁcult situations, with a reasonable rate of success
Fogang et al., 2012). For these guidelines to be improved, there is
n urgent need for improved diagnostic methods, which achieve
igh levels of both sensitivity and speciﬁcity.
.1. Neuroimaging
Neuroimaging is the preferred method for NCC diagnosis, using
T and MRI  scans it is possible to visualise infecting cysticerci and
ssess their number and location within the CNS. With experience,
he stage of the cyst lifecycle can be deﬁned: viable cysts appear
s small, round areas that are easily distinguished from the brain
arenchyma, with the scolex appearing as a nodule of high den-
ity within the cyst; degenerating cysts are far less well deﬁned
nd tend to be surrounded by an area of perilesional oedema (Del
rutto, 2012). A typical indicative pattern observed for NCC is theropica 166 (2017) 218–224 221
‘starry sky’ appearance formed by the presence of multiple cysts at
different evolutionary stages (Singhi and Suthar, 2015). CT scans are
cheaper and more commonly available, and also show higher sensi-
tivity for detection of calciﬁcations that occur in approximately 50%
of patients (Sinha and Sharma, 2009). The higher resolution of MRI
scans, permit better distinction of the degenerative stage of cys-
ticerci and can detect parasites located in sites that would be missed
by a CT scan, e.g. those located in the posterior fossa, basal cisterns
and ventricles (Takayanagui and Odashima, 2006). There are issues
with sensitivity, especially for intraventricular and subarachnoid
forms, where the cyst ﬂuid and CSF have such similar densities that
visualization is unlikely, even when using contrast-enhanced MRI
scans (Kimura-Hayama et al., 2010; Singhi and Suthar, 2015).
4.2. Immunological assays
Neuroimaging is expensive and requires both trained personnel
and technological resources that are not available in the majority of
low income countries in which NCC is endemic. This further reliance
on the use of serological testing for the detection of NCC. To date, the
lentil lectin puriﬁed glycoprotein (LLGP) enzyme-linked immuno-
electrotransfer blot (EITB) assay, which uses targeted antigens
to detect antibodies to T. solium in patient serum, has provided
the most consistent results (Fogang et al., 2015; Ito, 2015). This
diagnostic test has a reported speciﬁcity of 100%, with an overall
sensitivity of 98% (Garcia and Del Brutto, 2005); these rates signif-
icantly decline in cases where only a single cysticercus is present
as the low parasite load elicits a far weaker antibody response, and
sensitivity falling as low as 50% (Fogang et al., 2015; Ito, 2015). Anti-
bodies can persist in the serum for long periods after the parasite
has been cleared from the body and can be stimulated following
exposure to the parasite in the absence of an established infection
(Gilman et al., 2012). However, antibody responses have also been
shown to diminish within one year of surgery (Ito et al., 1999). In
addition, the presence of antibodies in the serum does not inform
as to the location of a cyst; testing positive for cysticercus infec-
tion is not synonymous with CNS involvement (Fogang et al., 2015;
Ito, 2015). These factors mean that the assay results should be
interpreted within the clinical context, and strengthen a suspected
diagnosis. There has been some debate as to whether NCC is best
detected in CSF rather than serum samples (Garcia and Del Brutto,
2005), but a recent comparative study by Sako et al. (2015) showed
no differences in sensitivity and speciﬁcity between samples of
serum and CSF.
New assays are in development that show promising results.
Gabriel et al. (2012) reported an ELISA based assay that could
detect T. solium antigens using monoclonal antibodies prepared
from T. saginata, indicating the presence of an established infec-
tion (as opposed to exposure only). A lateral ﬂow assay (LFA) has
recently been developed for the diagnosis and monitoring of extra-
parenchymal NCC (Fleury et al., 2016). This assay is based on the
use of the monoclonal antibody HP10. This assay, applied to CSF
samples correctly identiﬁed 34 cases of active extra-parenchymal
NCC, and gave negative results for 26 samples derived from treated
and cured NCC patients. The assay format is cheaper and is suitable
for laboratories that lack the ﬁnancial resources to support complex
diagnostic procedures (Fleury et al., 2016).
4.3. Stool microscopy
Traditional methods such as stool microscopy have been used
to visually assess the presence of T. solium eggs within the stool
of a potential carrier. Whilst this does not necessarily indicate an
NCC infection, it does assist in the detection of tapeworm carriers
and the consequent disruption of the cycle of transmission. Whilst
this method can have high speciﬁcity depending on the expertise
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Table 1
The ‘Del Brutto Criteria’ for diagnosis of NCC - adapted from Del Brutto et al. (2001).
Absolute Criteria Major Criteria Minor Criteria Epidemiological Criteria Diagnosis
Histology:
visualisation of parasite from
biopsy of brain or spinal cord
lesion.
Neuroimaging:
scolex visible within cystic
lesion.
Fundoscopy:
evidence of sub-retinal
Neuroimaging:
lesions highly suggestive of
NCC.
EITB assay:
positive result for detection of
T. solium antibodies.
Cysticidal drug therapy: lesion
resolution following treatment
with albendizole or
Neuroimaging:
lesions suggestive of NCC.
Clinical manifestations:
symptoms suggestive of NCC.
CSF ELISA:
positive detection for detection
of T. solium antibodies or
antigens.
Evidence of cysticercosis
NS.
Patient country of origin
endemic for NCC.
Patient currently resides in
NCC endemic area.
Patient frequently travels to
areas where NCC is endemic.
There is evidence that patient
household has had contact
with T. solium infection.
Deﬁnitive:
1 absolute
OR
2 major plus 1 minor/1
epidemiological.
Probable:
1  major plus 2 minor
OR
1  major plus 1 minor plus 1
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f the examiner, it has very low sensitivity due to a certain thresh-
ld of eggs needed to be visible under a microscope (Gilman et al.,
012). Molecular methods applied to stool samples, such as PCR
nd ELISA, may  improve detection rates but like so many other
vailable tests, the equipment and need for trained operators is
mpractical in many endemic settings (Mahanty and Garcia, 2010).
ore recently simpler and cheaper methods have been developed
or identiﬁcation of T. solium eggs (Nkouawa et al., 2016).
. Treatment
The heterogeneity of clinical presentations of NCC not only com-
licates the diagnostic procedure but also affects the management
lan for the disease; there can be no single, standard therapeutic
pproach when so many interconnecting factors must be consid-
red. Before commencing treatment, the complete disease proﬁle
ust be determined, including evidence of CNS involvement, char-
cterisation of the existing immune response, and the number,
ocation and viability of cysts present. Only once these factors have
een ascertained can a treatment plan that is tailored to the indi-
idual be determined.
.1. Cysticidal drugs
The use of cysticidal drugs in the treatment of NCC has attracted
ontroversy, as the use of such drugs may  pose more risk to the
atient than beneﬁt, due mostly to the extensive inﬂammatory
esponse that can be stimulated in response to the mass death of
ysts within the CNS (Sinha and Sharma, 2009). For this reason, the
se of cysticidal drugs is contraindicated in cases that have a pre-
xisting risk of developing hydrocephalus, such as in sub-arachnoid
CC and encephalitic NCC; in these situations, the inﬂammation
hat would occur following treatment may  pose a substantial risk
f rapidly raising ICP, and even result in death. Therefore, in cases
here a deﬁnitive diagnosis and characterisation of the infection
annot be provided due to lack of neuroimaging, it is considered
nwise to proceed with cysticidal therapy and patients should only
e treated with regards to their symptoms (Fogang et al., 2015).
urthermore, it has been suggested that alongside their potential
angers, cysticidal drugs may  also be unnecessary, as parenchymal
ysts in particular may  resolve naturally, following a completely
enign and asymptomatic pathway (Garcia et al., 2002). However,
everal studies have shown that cysticidal drugs do have a posi-
ive effect in reducing symptoms such as seizures and headaches,
nd hasten the resolution of parenchymal lesions; this argument
s strengthened by many clinicians’ apprehensions over allowing
 live parasite to continue its development in the brain without
hallenge (Sinha and Sharma, 2009; Singhi and Suthar, 2015).
The two most widely accepted cysticidal drugs are albendazole,
n imidazole that impairs glucose uptake and metabolism in the
arasite, and praziquantel, an isoquinolone that causes parasiteepidemiological
OR
3 minor plus 1 epidemiological.
paralysis by disrupting calcium pathways and homeostasis (Bobes
et al., 2014). These drugs are only applicable in the treatment of
viable cysts in the vesicular or early colloidal stages of develop-
ment, and are ineffective against calciﬁed cysts, as these represent
parasites that are already dead (Baird et al., 2013). Albendazole is
generally considered to be the drug of choice, with superior efﬁ-
cacy and antiparasitic effect compared to praziquantel, alongside
better CSF penetration, less apparent interaction with commonly
co-administered drugs such as corticosteroids and a more compet-
itive price (Fogang et al., 2015; Bansal et al., 2014). There remains a
lack of clarity surrounding prescription guidelines for these drugs
and confusion as to the clinical contexts in which their use is con-
sidered appropriate and beneﬁcial.
5.2. Anti-epileptics
Seizures are a commonly reported clinical manifestation of
parenchymal NCC. In cases involving evident symptoms and mul-
tiple viable cysts, anti-epileptic pharmacological therapy may
be indicated (Takayanagui and Odashima, 2006); drugs such as
phenobarbitone and carbamazepine are effective in controlling
NCC-related seizures in many cases (Del Brutto, 2012). One study
found that up to 50% of patients receiving anti-epileptic therapy for
NCC suffered relapses in seizure control following drug withdrawal,
suggesting that therapy was  having an inhibitory effect on seizures
stimulated by the presence of cysts (Garcia and Del Brutto, 2005).
Again, use of these drugs has attracted controversy, with some stud-
ies reporting no improvement in seizure outcome (Fogang et al.,
2015).
5.3. Steroids
Administration of steroids is a vital step in the regulation of
NCC-related inﬂammation in the CNS to control the acute inﬂam-
matory process that occurs following degradation of viable cysts.
Prednisolone or dexamethasone are commonly used as adjuncts
to cysticidal therapy and should be administered around 3 days
before the cysticidal drugs are administered, then continued for
approximately a week following the end of the course (Sinha and
Sharma, 2009). In patients with a heavy parasite load and diffuse
infection, the use of cysticidal therapy is considered too great a risk
and steroids may  be used in isolation (Fogang et al., 2015). Con-
comitant steroid administration has proven to be effective in the
prevention of severe inﬂammatory complications; however, there
are still some concerns regarding their use, including the potential
for increased parasite survival due to immune suppression and the
need for further studies into what constitutes appropriate doses
and timing of administration in order to provide optimum beneﬁts
(Carpio et al., 2013).
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.4. Surgery
In cases involving extensive infection, such as racemose NCC
nd severe extra-parenchymal NCC, anticysticidal therapy may  not
e an option due to risks associated with mass inﬂammation, but
hese types of NCC are associated with substantial risk of compli-
ations if left untreated. In these cases, a more aggressive approach
ay  be indicated, including cyst extirpation via surgery (Bansal
t al., 2014). More commonly, surgery may  be advised in severe
ases to insert shunts allowing for ﬂuid drainage and resolution of
ydrocephalus; shunt dysfunction in these cases is unfortunately
elatively common, and associated with increased mortality; simul-
aneous steroid administration can reduce this risk (Garcia et al.,
002). Surgery was the primary intervention for NCC therapy but
ith the development of advanced pharmacological therapeutics
n this ﬁeld, the use of surgery has signiﬁcantly declined, and is now
nly used in the severest of cases.
. Future prospects for control and prevention
Control and prevention of T. solium transmission should be a
ey priority in global health as intervention can reduce the sub-
tantial healthcare and economic burdens inﬂicted by both NCC
nd taeniasis (Torgerson and Macpherson, 2011).
The high biotic potential and environmental stability of tape-
orm eggs presents a signiﬁcant challenge for control but there
re a number of simple solutions that could easily be implemented
f ﬁnancial resources were made available to endemic countries.
mproved sanitation, increased education within communities to
ighlight and inform local populations as to the disease and cor-
alling pigs to prevent their contact with human waste are all
ssential components of any intervention in low and middle income
ountries (Schantz et al., 1993; Pawlowski, 2016). Increased aware-
ess of infection and transmission is also required in non-endemic
eveloped countries where the disease has shown signs of increas-
ng (Fabiani and Bruschi, 2013; Gilman et al., 2012) and where
uman carriers of T. solium require to be identiﬁed and treated on
ublic health grounds (Nkouawa et al., 2016).
One option for prevention and control of NCC is the development
f vaccines for application in pigs, of which the TSOL18 vaccine,
omprised of a recombinant protein originating from a T. solium
ncosphere shows promise (Jayashi et al., 2012). The sequencing of
he T. solium genome also offers exciting prospects in the further
mprovement of such vaccines through the identiﬁcation and direct
argeting of highly speciﬁc antigens (Bobes et al., 2014).
Finally, improved surveillance is needed, including implement-
ng obligatory notiﬁcation of NCC cases. Accurate assessment of
CC distribution and transmission, is critical to achieving robust
isease burden calculations and for targeting of public health
nterventions. Carpio et al. (2016) provides recommendations for
olicymakers for a range parasitic diseases affecting the CNS, and
f adopted, would provide much needed data that can be used
o direct future initiatives. In the absence of reliable estimates of
ts global burden, NCC will remain − along with other endemic
oonoses of low priority in the eyes of funding agencies (Maudlin
t al., 2009; Okello et al., 2015) − a truly neglected disease.
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